Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
Abstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcom...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-02-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-021-82615-4 |
| _version_ | 1818839931655553024 |
|---|---|
| author | Masahiro Yoshida Yosuke Nakaya Katsujun Shimizu Naoko Tatsumi Minako Tsutsumi Hoyuri Fuseya Mirei Horiuchi Takuro Yoshimura Yoshiki Hayashi Takafumi Nakao Takeshi Inoue Takahisa Yamane |
| author_facet | Masahiro Yoshida Yosuke Nakaya Katsujun Shimizu Naoko Tatsumi Minako Tsutsumi Hoyuri Fuseya Mirei Horiuchi Takuro Yoshimura Yoshiki Hayashi Takafumi Nakao Takeshi Inoue Takahisa Yamane |
| author_sort | Masahiro Yoshida |
| collection | DOAJ |
| description | Abstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0–22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment. |
| first_indexed | 2024-12-19T04:02:08Z |
| format | Article |
| id | doaj.art-4bc35587960143248af35001577f9702 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-12-19T04:02:08Z |
| publishDate | 2021-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-4bc35587960143248af35001577f97022022-12-21T20:36:39ZengNature PortfolioScientific Reports2045-23222021-02-011111710.1038/s41598-021-82615-4Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphomaMasahiro Yoshida0Yosuke Nakaya1Katsujun Shimizu2Naoko Tatsumi3Minako Tsutsumi4Hoyuri Fuseya5Mirei Horiuchi6Takuro Yoshimura7Yoshiki Hayashi8Takafumi Nakao9Takeshi Inoue10Takahisa Yamane11Department of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalDepartment of Pathology, Osaka City General HospitalDepartment of Hematology, Osaka City General HospitalAbstract Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0–22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment.https://doi.org/10.1038/s41598-021-82615-4 |
| spellingShingle | Masahiro Yoshida Yosuke Nakaya Katsujun Shimizu Naoko Tatsumi Minako Tsutsumi Hoyuri Fuseya Mirei Horiuchi Takuro Yoshimura Yoshiki Hayashi Takafumi Nakao Takeshi Inoue Takahisa Yamane Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma Scientific Reports |
| title | Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma |
| title_full | Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma |
| title_fullStr | Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma |
| title_full_unstemmed | Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma |
| title_short | Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma |
| title_sort | importance of diagnosis to treatment interval in newly diagnosed patients with diffuse large b cell lymphoma |
| url | https://doi.org/10.1038/s41598-021-82615-4 |
| work_keys_str_mv | AT masahiroyoshida importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT yosukenakaya importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT katsujunshimizu importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT naokotatsumi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT minakotsutsumi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT hoyurifuseya importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT mireihoriuchi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takuroyoshimura importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT yoshikihayashi importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takafuminakao importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takeshiinoue importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma AT takahisayamane importanceofdiagnosistotreatmentintervalinnewlydiagnosedpatientswithdiffuselargebcelllymphoma |